Bifidobacterium dentium

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Bifidobacterium dentium is a Gram-positive, non-spore-forming, anaerobic, non-motile, rod-shaped bacterium. It has been detected in at least 20 gut microbiome compilation studies or metastudies. The DNA G+C content is 61.2%. Bifidobacterium dentium is a common gut coloniser. (Scardovi1974)



  • This organism has been recovered from dental caries, human faeces (Sanz2007) and clinical sources (blood - CCUG). The risk classification (www.baua.de) for this organism is 2, i.e., risk of individual infection, but low risk of spread. Can cause opportunistic infections, particularly in immunocompromised people. Is a known gut commensal.
    • QUIRKS
  • Found in human breast milk (Jeurink2013).
    • GENERAL CHARACTERISTICS (Scardovi1974);
    Character Response
  • Substrates hydrolysed or digested:
  • aesculin;
  • 🌡
  • Temperature tolerance:
  • grows at 25℃; grows at 42℃; Grows optimally at 39-41℃.
  • H+
  • Acid from carbohydrates usually produced:
  • arabinose; fructose; galactose; glucose; mannose; ribose; xylose; amygdalin; starch; cellubiose; gentiobiose; lactose; maltose; melezitose; melibiose; raffinose; sucrose; trehalose; D-turanose; mannitol; arbutin; α-methyl glucoside; salicin;
  • ⥅
  • Substrates assimilated or utilised:
  • melibiose;
  • Active enzymes:
  • α-galactosidase; β-galactosidase; α-glucosidase; β-glucosidase; β-mannosidase;
    • SPECIAL FEATURES (Scardovi1974);
    Character Response
  • ✓
  • Metabolites produced:
  • lactate;
  • ✗
  • Metabolites not produced:
  • indole;
  • ✗
  • VP test:
  • not active
  • ✗
  • Nitrate:
  • not reduced
    • RESPONSE TO ANTIBIOTICS (Goldstein2003); (Matteuzzi1983); (Goldstein2013); (Goldstein2013a); (Citron2012a); (Citron2003);
    Class Active Resistant
  • Penicillins:
  • amoxicillin; amoxicillin-clavulanic acid; ampicillin; ampicillin-sulbactam; cloxacillin; imipenem; oxacillin; penicillin G; piperacillin; piperacillin-tazobactam; ticarcillin;
  • Cephalosporins:
  • cefotaxime; cefotetan; cefoxitin; cephalothin;
  • Macrolides:
  • erythromycin; fidaxomicin; pristinamycin; quinupristin-dalfopristin; spiramycin; telithromycin;
  • Tetracyclines:
  • minocycline; tetracycline;
  • Quinolines:
  • ciprofloxacin; gatifloxacin;
  • nalidixic-acid;
  • Aminoglycosides:
  • gentamicin; kanamycin; neomycin; streptomycin;
  • Polypep/ketides:
  • bacitracin; nisin A; rifampicin;
  • Heterocycles:
  • chloramphenicol; nitrofurantoin;
  • metronidazole;
  • Vancomycins:
  • vancomycin; teicoplanin;
  • Miscellaneous antibiotics:
  • clindamycin; daptomycin; lincomycin; linezolid; pristinamycin; telithromycin;
  • polymyxin B;
  • NOTES

    This is the only Bifidobacterium member that is a common inhabitant of the mouth, as well as the gut.

    Fuel sources used:
    It can use fibre, resistant starch, and simple sugars (including lactose) for energy.

    Metabolites produced:
    Our genomic analysis indicates that most members of this species can produce the following metabolites: acetate, B-glucuronidase, BCAAs, GABA, lactate, propionate, succinate, folate.

    Metabolites consumed:
    In addition, our genomic analysis indicates that most members of this species can consume the following metabolites: GABA, oxalate.

    Emerging research:
    Health associations involving this species are mixed. Mice models have shown this species can stimulate mucus production (which is important for a healthy gut) and it was a common species found in elderly Chinese over 100 years old. However elevated levels of this species were also observed in patients with rheumatoid arthritis.

  • References: [1] [2] [3] [4] [5]

  • Scardovi, V., & Crociani, F. (1974). Bifidobacterium catenulatum, Bifidobacterium dentium, and Bifidobacterium angulatum: Three New Species and Their Deoxyribonucleic Acid Homology Relationships. International Journal of Systematic Bacteriology, 24(2), 310–310.

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Actinobacteria Class:  Actinomycetia Order:  Bifidobacteriales Family:  Bifidobacteriaceae Genus:  Bifidobacterium Gram stain:  + O2 Relation.:  anaerobic Spore:  No spore Motility:  Sessile Morphology:  Rod
    Health:  Unknown
    Source:  dental caries, human faeces (Sanz2007) and clinical sources (blood - CCUG)
    DNA G+C(%):  61.2
    Opt. T:  39-41℃
    Lower T(℃):  25(+)
    High T(℃):  42(+)
    		Aesculin:  + Urea:  neg Gelatin:  neg Hippurate:  neg
    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    Arabinose:  + D-Arabinose:  neg Fructose:  + Fucose:  neg D-Fucose:  neg Galactose:  + Glucose:  + Mannose:  + Rhamnose:  neg Ribose:  + Sorbose:  neg D-Tagatose:  neg Xylose:  + L-Xylose:  neg Cellubiose:  + Gentiobiose:  + Lactose:  + Maltose:  + Melezitose:  + Melibiose:  + Sucrose:  + Trehalose:  + Turanose:  + Amygdalin:  + Dextrin:  neg Inulin:  neg Starch:  + Adonitol:  neg D-Arabitol:  neg L-Arabitol:  neg Dulcitol:  neg Erythritol:  neg Glycerol:  neg Inositol:  neg Mannitol:  + Sorbitol:  neg Xylitol:  neg Arbutin:  + Gluconate:  vr 2-Ketogluconate:  vr 5-Ketogluconate:  neg Me-α-D-Glc:  + Me-α-D-Mann:  neg Me-Xyloside:  neg NAc-α-GA:  neg Salicin:  +
    SUBSTRATE ASSIMILATION & UTILISATION
    Monosaccharide util/assim Oligosaccharide util/assim Other carboh. util/assim Amino acid util/assim Organic acid util/assim
    Melibiose:  +
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Oxidase:  neg Catalase:  neg Urease:  neg Ac-β-glcamnd:  neg α-Fucosidase:  neg α-Galactosidase:  + β-Galactosidase:  + α-Glucosidase:  + β-Glucosidase:  + β-Mannosidase:  + ArgDH:  neg GluDC:  neg AlanineAA:  vr AlaPheProAA:  neg GluGluAA:  neg GlyAA:  vr LeuAA:  vr LeuGlyAA:  neg PyrrolidAA:  neg AlkalineP:  neg
    METABOLITES - PRODUCTION & USE
    Fuel Usable Metabolites Metabolites Released Special Products Compounds Produced

    Fibre, Resistant Starch, Simple Sugars, Lactose

    GABA, Oxalate

    Branched-Chain AA, Folate, Acetate, Lactate, Propionate, Succinate, GABA

    Beta-glucuronidase

    		 Lactate:  + Indole:  neg
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    amoxicillin:  Sens
    Augmentin:  Sens
    ampicillin:  S(MIC50): 0.06, MIC90: 0.25, RNG: (0.06–1)
    amp-sulb:  S(MIC50): 0.06, MIC90: 0.125, RNG: (0.06–1)
    cloxacillin:  Sens
    oxacillin:  Sens
    penicillin_G:  S(MIC50): 0.125, MIC90: 0.5, RNG: (≤0.03-0.5)
    piperacillin:  Sens
    piper-taz:  S(MIC50): 0.06, MIC90: 0.5, RNG: (≤0.03-1)
    ticarcillin:  Sens
    imipenem:  S(MIC50): 0.06, MIC90: 0.06, RNG: (≤0.03-0.25)
    cefotaxime:  Sens
    cefotetan:  Sens
    cefoxitin:  S(MIC50): 1, MIC90: 4, RNG: (0.06–32)
    cephalothin:  Sens
    gentamicin:  Res
    kanamycin:  R(MIC50): 261, MIC90: 501, RNG: (200->1500)
    neomycin:  R(150-500)
    streptomycin:  R(100-300)
    erythromycin:  S(MIC50): 0.21, MIC90: 0.43, RNG: (0.1-0.5)
    fidaxomicin:  S(MIC50): 0.125, MIC90: 0.125, RNG: (0.03–0.25)
    pristinamycin:  Sens
    quin-dalf:  S(MIC50): 0.25, MIC90: 0.25, RNG: (0.125-0.5)
    spiramycin:  Sens
    telithromycin:  Sens
    linezolid:  S(MIC50): 1, MIC90: 1, RNG: (0.25–2)
    ciprofloxacin:  Sens
    gatifloxacin:  Sens
    moxifloxacin:  Var(MIC50): 1, MIC90: 8, RNG: (0.06–16)
    nalidixic-acid:  R(>200)
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    minocycline:  Sens
    tetracycline:  S(MIC50): 3.6, MIC90: 4.7, RNG: (3-5)
    teicoplanin:  S(MIC50): 0.25, MIC90: 0.5, RNG: (0.125–0.5)
    vancomycin:  S(MIC50): 0.5, MIC90: 1, RNG: (0.25-1)
    bacitracin:  S(MIC50): <0.8, MIC90: 1.3, RNG: (0.8-1.3)
    nisin_A:  Sens
    rifampicin:  Sens
    chloramphenicol:  S(MIC50): 5.1, MIC90: 5.8, RNG: (5-6)
    metronidazole:  R(MIC50): 32, MIC90: >32, RNG: (0.125->32)
    nitrofurantoin:  S(MIC50): 22, MIC90: 44, RNG: (15-60)
    clindamycin:  S(MIC50): 0.06, MIC90: 0.06, RNG: (0.06–0.125)
    lincomycin:  Sens
    daptomycin:  S(MIC50): 0.25, MIC90: 0.5, RNG: (≤0.03-1)
    polymyxin_B:  R(>700)

    References

    SPECIFIC REFERENCES FOR BIFIDOBACTERIUM DENTIUM
  • Goldstein2003 - In Vitro Activities of Daptomycin, Vancomycin, Quinupristin- Dalfopristin, Linezolid, and Five Other Antimicrobials against 307 Gram-Positive Anaerobic and 31 Corynebacterium Clinical Isolates.
  • Matteuzzi1983 - Antimicrobial susceptibility of Bifidobacterium.
  • Scardovi1974 - Bifidobacterium catenulatum, Bifidobacterium dentium, and Bifidobacterium angulatum: Three New Species and Their Deoxyribonucleic Acid Homology Relationships.
  • Dubinkina2017 - Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease
  • Finegold2010 - Pyrosequencing study of fecal microflora of autistic and control children
  • Gryp2020 - Isolation and Quantification of Uremic Toxin Precursor-Generating Gut Bacteria in Chronic Kidney Disease Patients
  • Li2019c - Gut Microbiota Differs Between Parkinson's Disease Patients and Healthy Controls in Northeast China
  • Vatanen2018 - The human gut microbiome in early-onset type 1 diabetes from the TEDDY study
  • Xu2012 - Changes of fecal Bifidobacterium species in adult patients with hepatitis B virus-induced chronic liver disease
  • Ye2020 - Altered gut microbiome composition in patients with Vogt-Koyanagi-Harada disease
  • Zhu2020 - Metagenome-wide association of gut microbiome features for schizophrenia
  • Goldstein2013 - In vitro activity of Biapenem plus RPX7009, a carbapenem combined with a serine β-lactamase inhibitor, against anaerobic bacteria.
  • Goldstein2013a - Comparative in vitro activities of SMT19969, a new antimicrobial agent, against Clostridium difficile and 350 gram-positive and gram-negative aerobic and anaerobic intestinal flora isolates.
  • Citron2012a - Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria.
  • Citron2003 - In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria.
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR BIFIDOBACTERIUM DENTIUM
  • Almeida2019 - A new genomic blueprint of the human gut microbiota.
  • Byrd2020 - Stability and dynamics of the human gut microbiome and its association with systemic immune traits.
  • Chen2020 - Structural and Functional Characterization of the Gut Microbiota in Elderly Women With Migraine
  • Chen2020a - Featured Gut Microbiomes Associated With the Progression of Chronic Hepatitis B Disease
  • Dubinkina2017 - Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease
  • Forster2019 - A human gut bacterial genome and culture collection for improved metagenomic analyses.
  • Hu2019 - The Gut Microbiome Signatures Discriminate Healthy From Pulmonary Tuberculosis Patients
  • Jie2017 - The gut microbiome in atherosclerotic cardiovascular disease
  • Karlsson2013 - Gut metagenome in European women with normal, impaired and diabetic glucose control
  • King2019 - Baseline human gut microbiota profile in healthy people and standard reporting template.
  • Lagier2016 - Culture of previously uncultured members of the human gut microbiota by culturomics.
  • MacFarlane2004 - Chemotaxonomic analysis of bacterial populations colonizing the rectal mucosa in patients with ulcerative colitis.
  • Mangin2004 - Molecular inventory of faecal microflora in patients with Crohn's disease.
  • New2022 - Collective effects of human genomic variation on microbiome function.
  • RajilicStojanovic2014 - The first 1000 cultured species of the human gastrointestinal microbiota.
  • Tyakht2013 - Human gut microbiota community structures in urban and rural populations in Russia.
  • Wang2018 - A metagenome-wide association study of gut microbiota in asthma in UK adults
  • Wang2018a - Morphine induces changes in the gut microbiome and metabolome in a morphine dependence model.
  • Wang2020a - Aberrant gut microbiota alters host metabolome and impacts renal failure in humans and rodents
  • Woodmansey2004 - Comparison of compositions and metabolic activities of fecal microbiotas in young adults and in antibiotic-treated and non-antibiotic-treated elderly subjects.
  • Zeller2014 - Potential of fecal microbiota for early-stage detection of colorectal cancer
  • ...............................
    • GENERAL REFERENCES FOR BIFIDOBACTERIUM DENTIUM
  • Sanz2007 - Differences in faecal bacterial communities in coeliac and healthy children as detected by PCR and denaturing gradient gel electrophoresis
    • Added: February 08, 2021